Liposomal formulations of cyclosporin A: A biophysical approach to pharmacokinetics and pharmacodynamics

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 18, Issue 2, 2001, Pages 141-172

  Fahr, A ^a   Seelig, J ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Biophysics; Cyclosporin A; Formulation; Liposome; Pharmacokinetics

Indexed keywords

CYCLOSPORIN A DERIVATIVE; LIPOSOME;

AREA UNDER THE CURVE; DRUG BINDING; DRUG DISTRIBUTION; DRUG EFFECT; DRUG FORMULATION; DRUG STRUCTURE; HUMAN; HYPERTENSION; LIPOPHILICITY; LIVER TOXICITY; NEPHROTOXICITY; NONHUMAN; REVIEW;

BIOPHYSICS; CYCLOSPORINE; IMMUNOSUPPRESSIVE AGENTS; LIPOSOMES;

EID: 0035041044     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (106)

1. Cyclosporin A in patients receiving renal allografts from cadaver donors
2. Cyclosporin A for the treatment of graft-versus-host disease in man
3. In vivo pharmacological effects of cyclosporin and some analogues
4. Modeling conformational changes in cyclosporin A
5. Cyclosporin A inhibits the interleukin 2 receptor alpha chain gene transcription but not its cell surface expression: The alpha chain stability can explain this discrepancy
6. The mechanisms of action of cyclosporin A in the treatment of psoriasis
7. Cyclosporin A rapidly inhibits epidermal cytokine expression in psoriasis lesions, but not in cytokine-stimulated cultured keratinocytes
8. GRO-alpha mRNA is selectively overexpressed in psoriatic epidermis and is reduced by cyclosporin A in vivo, but not in cultured keratinocytes
9. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases
10. The spectrum of cyclosporin nephrotoxicity [clinical conference]
11. Chemistry of the natural cyclosporin metabolites
12. Interactions of Cyclosporin A and some derivatives with model membranes: Binding and ion permeability changes
13. Restrictive transport of a lipid-soluble peptide (cyclosporine) through the blood-brain barrier
14. Solvent dependent conformation and hydrogen-bonding capacity of cyclosporin A: Evidence from partition coefficients and molecular dynamics simulations
15. Problems with therapeutic monitoring of cyclosporine using silicone central venous line samples
16. Interaction of a voltage-sensitive dye and amphiphilic peptides with lipid membranes: Titration calorymetry and solid state NMR studies
17. Titration colorimetry of lipid-peptide interactions
18. Drug delivery systems for cyclosporine: Achievements and complication
19. Renal side effects of Cyclosporin A
20. Effects of cyclosporine on the isolated perfused rat kidney
21. Acutely impaired renal function during intravenous administration of cyclosporine A: A cremophor side-effect
22. Complement-mediated reachtions to dazepam with Cremophor as solvent (Stelosid MR)
23. Suspected anaphylactic reaction to Cremophor EL
24. Pharmacology of an emulsion formulation of ICI 35 868
25. Histamine release and hypotensive reactions in dogs by solubilizing agents and fatty acids: Analysis of various components in cremophor EL and development of a compound with reduced toxicity
26. Anaphylactic reaction and cardiopulmonary arrest following intravenous cyclosporine
27. Anaphylactic reaction to intravenous cyclosporin
28. Novel drug delivery system opens new frontiers in immunosuppression
29. Cyclosporine absorption from microemulsion formulation in liver transplant recipients
30. Dissolving intravenous cyclosporin-A in a fat emulsion carrier prevents acute renal side effects in the rat
31. Pharmacokinetics of two alternative dosage forms for cyclosporine: Liposomes and intralipid
32. Compatibility of cyclosporine with fat emulsion
33. Differential distribution of liposome-entrapped [3H]methotrexate and labelled lipids after intravenous injection in a primate
34. The organ distribution of liposome encapsulated and free cobalt in rats: Liposomes decrease the cardiac uptake of the metal
35. A comparative study on the antitumor effect, cardiotoxicity and nephrotoxicity of doxorubicin given as a bolus, continuous infusion or entrapped in liposomes in the Lou/M Wsl rat
36. Biodistribution studies of liposome encapsulated hemoglobin (LEH) studied with a newly developed 99m-technetium liposome label
37. Differential uptake of gallium-67-labeled liposomes between tumors and inflammatory lesions in rats
38. Technetium-labelled liposome imaging for deep-seated infection
39. Tissue distribution of EDTA encapsulated within liposomes of varying surface properties
40. Pharmacokinetics of liposome encapsulated cisplatin in rats
41. Use of liposomes as injectable-drug delivery systems
42. Aerosolized cyclosporine as single-agent immunotherapy in canine lung allografts
43. Ocular bioavailability of cyclosporine after oral administration
44. Preparation and efficacy of cyclosporin-A liposomes for prolongation of cardiac allograft survival
45. Liposomal formulation eliminates acute toxicity and pump incompatibility of parenteral cyclosporine
46. Effect of coadministration of Intralipid™ on the pharmacokinetics of cyclosporine in the rabbit
47. Human-plasma lipoproteins and total parenteral nutrition with intravenous fat emulsion
48. Physicochemical characterization of Intralipid emulsions
49. Pharmacokinetic and pharmacodynamic evaluation of liposomal cyclosporine
50. Tissue distribution and in vivo immunosuppressive activity of liposomal cyclosporine
51. Efficacy of incorporating cyclosporine into liposomes to reduce its nephrotoxicity
52. Reduced nephrotoxicity of cyclosporine A after incorporation into liposomes
53. The pharmacokinetics of cyclosporine, II: Blood plasma distribution and binding studies
54. Evidence that liposome incorporation of cyclosporine reduces its toxicity and potentiates its ability to prolong survival of cardiac allografts in mice
55. Liposome-bound cyclosporine: Clearance after intravitreal injection
56. Prolongation of corneal allograft survival with liposome-encapsulated cyclosporine in the rat eye
57. Topical ciclosporin for psoriasis: In vitro skin penetration and clinical study
58. Topical delivery of ciclosporin: Evaluation of various formulations using in vitro diffusion studies in hairless mouse skin
59. Topical application of liposomally entrapped cyclosporin evaluated by in vitro diffusion studies with human skin
60. Binding of cyclosporine by human lymphocytes and phospholipid vesicles
61. Effect of Cyclosporine A on biomembranes: Vibrational spectroscopic, calorimetric and hemolysis studies
62. Interactions of cyclosporin A with phospholipid membranes: Effect of cholesterol
63. Interaction of Cyclosporin A with dipalmitoylphosphatidylcholine
64. Liposomes as cyclosporin A carriers: The influence of ordering of hydrocarbon chains of phosphatidylglycerol liposomes on the association with and topography of cyclosporin
65. FK506 and ciclosporin: Molecular probes for studying intracellular signal transduction
66. Free cytoplasmic calicum concentration and the mitogenic stimulation of lymphocytes
67. 2+ level of human lymphoid cell lines and mouse lymphocytes
68. Activation and proliferation signals in mouse B cells: VII CA2+ ionophores are nonmitogenic polyclonal B cell activators
69. The activation of lymphocytes by the ionophore A23187
70. A serine protease triggers the initial step of transmembrane signalling in cytotoxic T cells
71. Cyclosporine A induces an early and transient rigidification of lymphocyte membranes
72. Glomerulotubular function in long term renal allograft recipients
73. Effect of cyclosporine on the diluting capacity of the rat kidney
74. Liposomes as cyclosporin A carriers: ESR study of cyclosporin A interaction with 1,2-dimyristoyl-sn-3-phosphatidylglycerol liposomes
75. Liposomal cyclosporine: Characterization of drug incorporation and interbilayer exchange
76. Cyclosporin partitions into phospholipid vesicles and disrupts membrane architecture
77. Cyclosporin A and the permeability of the cytoplasmic membrane in Aspergillus niger
78. Cyclosporin: Li- and Ca-specific ionophore!
79. Biophysical characterization of liposomal delivery systems for lipophilic drugs: Cyclosporin A as an example
80. Cyclosporine transfer from low- and high-density lipoproteins is partially influenced by lipid transfer protein I triglyceride transfer activity
81. Liposome disposition in vivo: Effects of pre dosing with liposomes
82. Liposome disposition in vivo, III: Dose and vesicle-size effects
83. Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters
84. Distribution and transfer of cyclosporine among the various human lipoprotein classes
85. Physiologic modeling of cyclosporin kinetics in rat and man
86. Interaction of cyclosporin A with human lipoproteins
87. Liposomal formulations of Cyclosporin A: Influence of lipid type and dose on pharmacokinetics
88. Cyclosporine disposition in the hyperlipidemic rat model
89. In vivo interaction of cyclosporine and intralipid
90. Liposomal cyclosporine: Comparison of drug and lipid carrier pharmacokinetics and biodistribution
91. Characterization, stability and in vivo targeting of liposomal formulations containing cyclosporin
92. Cyclosporine liposomes: In vitro stability and in vivo nephrotoxicity evaluation
93. Cyclosporine A administration: Once a day or in fractional doses?
94. Aquatic models for the study of renal transport function and pollutant toxicity
95. Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood
96. The conformation of Cyclosporin A in the crystal and solution
97. Preliminary report: The use of liposome-encapsulated cyclosporine in a rat model
98. Effect of liposome encapsulation on the toxicity of cyclosporin A